Literature DB >> 588413

Monocyte chemotaxis in bronchial carcinoma and cigarette smokers.

A B Kay, J G McVie.   

Abstract

Chemotaxis of blood monocytes was measured in 31 patients with bronchial carcinoma and 19 cigarette smokers. Thirteen patients with metastatic bronchial carcinoma had significantly less (P less than 0.005) chemotactic response than matched controls. Those with disease confined to the chest, or with recurrent or operable bronchial carcinoma, had no significant depression of monocyte chemotaxis. There was also no significant difference in monocyte chemotaxis between cigarette smokers and matched controls. These results support the concept that in human cancer there is a defect in monocyte chemotaxis, but in bronchial carcinoma significant depression was only apparent in those with advanced disease.

Entities:  

Mesh:

Year:  1977        PMID: 588413      PMCID: PMC2025378          DOI: 10.1038/bjc.1977.215

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma.

Authors:  R H Rubin; A B Cosimi; E J Goetzl
Journal:  Clin Immunol Immunopathol       Date:  1976-11

2.  An inhibitor of macrophage chemotaxis produced by neoplasms.

Authors:  R Snyderman; M C Pike
Journal:  Science       Date:  1976-04-23       Impact factor: 47.728

3.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

4.  Control of carcinogenesis: a possible role for the activated macrophage.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Science       Date:  1972-09-15       Impact factor: 47.728

5.  Human mononuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic factors.

Authors:  R Snyderman; L C Altman; M S Hausman; S E Mergenhagen
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

6.  Defective monocyte function in patients with genitourinary carcinoma.

Authors:  M S Hausman; S Brosman; R Snyderman; M R Mickey; J Fahey
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

7.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

8.  Human eosinophils, acidic tetrapeptides (ECF-A) and histamine. Interactions in vitro and in vivo.

Authors:  L W Turnbull; D P Evans; A B Kay
Journal:  Immunology       Date:  1977-01       Impact factor: 7.397

9.  Eosinophils and mediators of anaphylaxis. Histamine and imidazole acetic acid as chemotactic agents for human eosinophil leucocytes.

Authors: 
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

10.  Letter: Surveillance against neoplastic cells-is it mediated by macrophages?

Authors:  P Alexander
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

  10 in total
  9 in total

1.  A monocyte function test (complement receptor enhancement) to assess the extent of bronchial carcinoma.

Authors:  M Carroll; M J Smith; M E Hodson; A B Kay
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

2.  Leucoattractants enhance complement receptors on human phagocytic cells.

Authors:  A B Kay; E J Glass; D M Salter
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

3.  Defective chemotactic factor-induced monocyte complement receptor enhancement in lung cancer.

Authors:  M Carroll; K Lukacs; M Hodson; A B Kay
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

Review 4.  Disordered function of mononuclear phagocytes in malignant disease.

Authors:  R J Sokol; G Hudson
Journal:  J Clin Pathol       Date:  1983-03       Impact factor: 3.411

5.  Monocyte antibody-dependent cellular cytotoxicity in cancer patients.

Authors:  N J De Young; P G Gill
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma.

Authors:  H Nielsen; J Bennedsen; S O Larsen; P Dombernowsky; K Viskum
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Inhibition of monocyte complement receptor enhancement by low molecular weight material from human lung cancers.

Authors:  E J Glass; C A Abell; A B Kay
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

8.  Effect of autologous and homologous serum and circulating immune complexes on monocyte functions of patients with solid tumours.

Authors:  A Celada; T Aguado; P H Lambert; A Cruchaud
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

9.  "Activated" monocytes in gastric cancer patients. I. Increased Fc receptor expression, antibody-dependent cellular cytotoxicity and NBT reduction.

Authors:  W Uracz; A Pituch-Noworolska; M Zembala; T Popiela; A Czupryna
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.